Wolfgang Miesbach: New Research Reveals Clonogenic Hepatocytes as the Key Drivers of Liver Growth and Gene Therapy Success
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“Only 15-20% of newborn hepatocytes generate 90% of adult liver tissue. New research from San Raffaele Telethon Institute characterizes hepatocyte heterogeneity and reveals that ‘clonogenic hepatocytes‘ – a small subset of liver cells in newborn mice – are responsible for most adult liver growth:
- Gene editing by HDR preferentially targets these clonogenic cells, expanding edited liver areas during growth
- Lentiviral vectors show age-dependent efficiency – higher in newborns, lower in adults (reversible with proteasome inhibition)
- Peri-central hepatocyte identity develops after weaning
- Clonogenic hepatocytes co-localize with hematopoietic progenitor cells in specialized tissue niches research
Gene Therapy Impact:
This discovery transforms pediatric gene therapy timing and targeting strategies. Understanding when and which hepatocytes to target could unlock more effective treatments for inherited liver diseases
The team used cutting-edge single-cell/spatial transcriptomics, clonal tracing, and mathematical modeling to map hepatocyte proliferation and maturation after birth
Congratulations to Alessio Cantore, Michela Milani, Francesco Starinieri, Matteo Iannacone, Renato Ostuni, Giulia Bortolussi, Ivan Merelli, Stefano Beretta, Marco Monti!”
Title: Spatiotemporal liver dynamics shape hepatocellular heterogeneity and impact in vivo gene engineering
Authors: Michela Milani, Francesco Starinieri, Stefano Beretta, Marco Monti, Cesare Canepari, Francesca Marabotti, Samuel Zambrano, Davide Mazza, Anna Fabiano, Chiara Simoni, Eugenia Cammarota, Monica Volpin, Giulia Bortolussi, Fabio Russo, Mauro Biffi, Marco Genua, Sara Degl’Innocenti, Francesca Sanvito, Renato Ostuni, Andrés F. Muro, Eugenio Montini, Federica Moalli, Matteo Iannacone, Ivan Merelli, Alessio Cantore
Read the full article here.
More recent insights on Hemostasis Today.
-
Sep 2, 2025, 08:51Perioperative Direct Oral Anticoagulant (DOAC) Dosing: Insights Dr. Sthanu Subramanian
-
Sep 2, 2025, 08:49Why Polycythemia Vera Doesn’t Raise EPO Levels Explained by William Aird
-
Sep 2, 2025, 08:47SUGAR Trial in Heart BMJ: Stent Outcomes in Patients With Diabetes Under the Spotlight
-
Sep 2, 2025, 08:43Eltrombopag with Immunosuppressive Therapy Shows Promising Safety in Pediatric Severe Aplastic Anemia – Phase 2 ESCALATE Trial Results
-
Sep 2, 2025, 08:14Mirvat Alasnag Discusses OPTION-STEMI Findings Published in The Lancet
-
Sep 1, 2025, 15:31Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
-
Sep 1, 2025, 07:39Flora Peyvandi: Reappraising Hemostasis Testing in Cirrhosis
-
Sep 1, 2025, 07:35Dario Bongiovanni Presents Milestone Discovery on Reticulated Platelets at ESC Congress 2025
-
Sep 1, 2025, 07:19Felice Gragnano: Clopidogrel vs Aspirin for Secondary Prevention in Coronary Artery Disease – Meta-Analysis Shows Superior MACCE Protection
-
Sep 1, 2025, 07:18Wolfgang Miesbach: New Research Reveals Clonogenic Hepatocytes as the Key Drivers of Liver Growth and Gene Therapy Success
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Sep 1, 2025, 08:09Wafik S. El-Deiry Opens Up on Recovery, Gratitude, and Book After Life-Changing Heart Surgery
-
Aug 31, 2025, 07:30Michael Albert: Being ‘Metabolically Healthy’ Doesn’t Eliminate Heart Disease Risk
-
Aug 31, 2025, 07:15Should 12-Month DAPT Be the Default After ACS? Mattia Galli Applauds Marco Valgimigli’s Talk
-
Aug 31, 2025, 07:10Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
-
Aug 30, 2025, 14:45Gordon’s Journey: 60 Years of Life After DVT Managed with Warfarin